Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains by Lemoine, Laetitia et al.
RESEARCH Open Access
Comparative binding properties of the tau
PET tracers THK5117, THK5351, PBB3, and
T807 in postmortem Alzheimer brains
Laetitia Lemoine1, Per-Göran Gillberg1, Marie Svedberg2, Vladimir Stepanov2, Zhisheng Jia2, Jinghai Huang3,
Sangram Nag2, He Tian3, Bernardino Ghetti4, Nobuyuki Okamura5, Makoto Higuchi6, Christer Halldin2
and Agneta Nordberg1,7*
Abstract
Background: The aim of this study was to compare the binding properties of several tau positron emission
tomography tracers—THK5117, THK5351, T807 (also known as AV1451; flortaucipir), and PBB3—head to head in the
same human brain tissue.
Methods: Binding assays were performed to compare the regional distribution of 3H-THK5117 and 3H-THK5351 in
postmortem tissue from three Alzheimer’s disease (AD) cases and three control subjects in frontal and temporal
cortices as well as in the hippocampus. Competition binding assays between THK5351, THK5117, PBB3, and T807, as
well as off-target binding of THK5117 and T807 toward monoamine oxidase B (MAO-B), were performed using
binding assays in brain homogenates and autoradiography of three AD cases.
Results: Regional binding of 3H-THK5117 and 3H-THK5351 was similar, except in the temporal cortex, which
showed higher 3H-THK5117 binding. Saturation studies demonstrated two binding sites for 3H-THK5351 (Kd1 = 5.6
nM, Bmax = 76 pmol/g; Kd2 = 1 nM, Bmax = 40 pmol/g). Competition studies in the hippocampus between
3H-
THK5351 and unlabeled THK5351, THK5117, and T807 revealed super-high-affinity sites for all three tracers (THK5351
Ki = 0.1 pM; THK5117 Ki = 0.3 pM; T807 Ki = 0.2 pM) and an additional high-affinity site (THK5351 Ki = 16 nM; THK5117
Ki = 20 nM; T807 Ki = 78nM).
18F-T807, 11C-THK5351, and 11C-PBB3 autoradiography of large frozen sections from
three AD brains showed similar regional binding for the three tracers, with lower binding intensity for 11C-PBB3.
Unlabeled THK5351 and T807 displaced 11C-THK5351 to a similar extent and a lower extent, respectively, compared
with 11C-PBB3. Competition with the MAO-B inhibitor 3H-L-deprenyl was observed for THK5117 and T807 in the
hippocampus (THK5117 Ki = 286 nM; T807 Ki = 227 nM) and the putamen (THK5117 Ki = 148 nM; T807 Ki = 135 nM).
3H-THK5351 binding was displaced using autoradiography competition with unlabeled THK5351 and T807 in
cortical areas by 70–80% and 60–77%, respectively, in the basal ganglia, whereas unlabeled deprenyl displaced 3H-
THK5351 binding by 40% in the frontal cortex and 50% in the basal ganglia.
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Conclusions: THK5351, THK5117, and T807 seem to target similar binding sites, but with different affinities, whereas
PBB3 seems to target its own binding site. Both THK5117 and T807 demonstrated off-target binding in the
hippocampus and putamen with a ten times lower binding affinity to the MAO-B inhibitor deprenyl compared with
3H-THK5351.
Keywords: Alzheimer’s disease, THK5117, 11C-THK5351, T807, AV1451, PBB3, Tau imaging, autoradiography, Tau PET,
Tau PET tracers, Deprenyl
Background
Accumulation of tau protein is one of the main hall-
marks of Alzheimer’s disease (AD), along with amyloid
deposition and astrocytosis. In recent years, several at-
tempts have been made to develop positron emission
tomography (PET) tracers that are able to visualize tau
deposits in vivo.
The complexity of developing a ligand targeting tau
protein is increased because of its intracellular location.
The first compound used to target tau deposits in vivo
was 2-(1-{6-[(2-[fluorine-18]fluoroethyl)(methyl)amino]-
2-naphthyl}-ethylidene)malononitrile (FDDNP), which
was developed as an amyloid tracer but also showed
some binding to neurofibrillary tangles (NFTs). Unfortu-
nately, because of its affinity for amyloid plaques and
lack of selectivity to NFTs, FDDNP is not suitable for
tau imaging [1–3]. Recently, several tau PET tracers have
been developed and tested in vitro and in preclinical im-
aging, showing good results and leading to their inclu-
sion in clinical studies. In this study, we focused on the
THK tracer family as well as PBB3 and T807. First, 11C-
PBB3 has been reported to be a good candidate for in
vivo PET imaging and autoradiography with 11C-PBB3
in PS19-transgenic mice, showing binding in the same
area as the fluorescent Congo red derivative (trans,-
trans)-1-fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)s-
tyrylbenzene, indicating the presence of tau filaments [4,
5]. Moreover, autoradiography experiments in human
brain tissue showed binding to NFTs in the hippocam-
pus and no colocalization with 11C-Pittsburgh com-
pound B (PIB) [4]. In vitro characterization of AV-1451
using autoradiography showed a good affinity for paired
helical filaments (PHF-tau), as well as good colocaliza-
tion, in comparison with PHF-tau immunohistochemis-
try, in addition to a correlation with the NFT deposition
in the different Braak stages [6–9]. Binding assay experi-
ments performed on AD brain homogenates using 3H-
THK5117 demonstrated several binding sites in both
temporal and hippocampal regions [10]. THK5117 and
THK5351, the latest derivatives of the aryquinoline
series, have shown good affinity for PHF-tau [11].
THK5351, which is the S-form of THK5151, has been
reported to bind less than other tau tracers to white
matter [12, 13]. Because extensive in vitro data are
available for all the tracers in AD brain tissue, some
studies have been focused on non-AD tauopathies [14].
In recent studies, both in vitro and in vivo experiments
have shown that the different tau PET tracers bind to
different tau deposits (see [15] for review). The tau pro-
tein can have either three repeats (3R) or four repeats
(4R) of the microtubule-binding domain regarding inclu-
sion or exclusion of exon 10 during alternative splicing.
The affinity of the tracer appears to depend on the in-
clusion of 3R, 4R, or both [16–19].
Off-target binding of the different tau tracers has been
observed in regions poor in PHF-tau. The location of
this off-target binding in the basal ganglia led some re-
search groups to suggest the possibility of binding to
monoamine oxidase (MAO) (see [15] for review). In a
recent study done at McGill University, Ng et al. showed
that pretreatment with selegiline, a MAO-B inhibitor, re-
duced the in vivo PET uptake of 18F-THK5351 [20] and
confirmed those results in vitro. Furthermore, our group
recently showed that the affinity between MAO-B and
THK5117 occurred at around 300 nM, implying that it
should not affect the signal observed by PET [21]. Previ-
ous in vitro studies have also indicated that T807 binds
to MAO-A [22, 23].
The aim of this study was to compare the two THK
compounds THK5117 and THK5351 with T807 and
PBB3 in head-to-head autoradiography and binding
assay studies in the same human brain tissue. To our
knowledge, this is the first report of the binding of 11C-




yl)oxy)propan-2-ol (3H-THK5117; specific activity
2.2 GBq/μmol) and unlabeled THK5117 were custom-
synthesized by Quotient Bioresearch/Pharmaron (Car-
diff, UK). 3H-THK5351, 11C-THK5351 [(S)-1-fluoro-3-
(2-(6-([11C]methylamino)pyridin-3-yl)quinolin-6-yloxy)-
propan-2-ol], 11C-PBB3 [(5-((1E,3E)-4-(6-[11C] methyla-
mino)pyridin-3-yl)buta-1,3-dien-1-yl)benzo[d]thiazol-6-
ol], and 18F-T807 [7-(6-[18F]fluoropyridin-3yl)-5H-pyr-
ido(4,3-b)indole] were synthesized and labeled at the
Centre for Psychiatric Research in the Department of
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Clinical Neuroscience (Karolinska Institutet, Solna,
Sweden). NO and MH provided the THK5351 and PBB3
precursors, respectively. Unlabeled T807 and tert-buty-
loxycarbonyl-protected precursors were synthesized by
HT. (R)-(−)-deprenyl hydrochloride was purchased from
Tocris Bioscience (Bristol, UK).
In vitro binding assay
Postmortem brain tissues from three patients with AD
and three healthy control subjects were used for the in
vitro binding assays. All the brain tissue, which came
from the Netherlands Brain Bank, had been homoge-
nized in PBS containing a protease/phosphatase inhibi-
tor (see Table 1).
The saturation binding experiment was carried out
using increasing concentrations of 3H-THK5351 (0.1–
250 nM) in hippocampus AD brain homogenate
(0.2 mg/ml) to determine the dissociation constant
(Kd). Nonspecific binding was determined using 1 μM
unlabeled THK5117. After 2-h incubation at room
temperature, the binding assay was terminated by fil-
tration through glass fiber filters presoaked for at
least 3 h in 0.3% polyethylenimine. To do so, the fil-
ters were rinsed and filtered three times using cold
binding buffer, and then the radiation on the filter
was quantified using a scintillation counter (Beckman
Coulter, Brea, CA, USA).
The regional binding distribution comparison between
3H-THK5351 and 3H-THK5117 was carried out in post-
mortem frontal and temporal cortical and hippocampal
tissue from the brains of three patients with AD and
three control subjects. The protocol was similar for 3H-
THK5351 (1.5 nM) and 3H-THK5117 (3 nM): 0.1 mg of
tissue in PBS + 0.1% bovine serum albumin (BSA) to a
final volume of 500 μl, followed by incubation for 2 h at
room temperature. The nonspecific binding was deter-
mined using 1 μM unlabeled THK5351 or unlabeled
THK5117. After 2-h incubation at room temperature,
the competition binding assay was stopped using filtra-
tion through glass fiber filters, and the radiation was
then quantified using the scintillation counter.
Competition binding studies using postmortem hippo-
campus brain homogenate (0.2 mg/ml tissue) from three
patients with AD were performed using 3H-THK5351
(1.5 nM) as well as increasing concentrations of un-
labeled THK5351 (10−14 to 10−5 nM), THK5117 (10−14
to 10−5 nM), and T807 (10−14 to 10−5 nM), to determine
the inhibition constant (Ki). After 2-h incubation at
room temperature, the binding assay was terminated by
filtration through glass fiber filters presoaked for at least
3 h in 0.3% polyethylenimine. To do so, the filters were
rinsed and filtered three times using cold binding buffer,
and then the radiation on the filter was quantified using
a Beckman Coulter scintillation counter. The data for
the regional binding distribution studies were analyzed
using Prism version 7.0 software for Mac (GraphPad
Software Inc., La Jolla, CA, USA), and two-way analysis
of variance with multiple comparisons was performed.
Competition binding studies using postmortem brain
homogenates from the hippocampus and putamen
(0.2 mg/ml tissue) of two patients with AD were per-
formed using 3H-deprenyl (10 nM in Na-K phosphate
buffer, pH 7.4) and increasing concentrations of un-
labeled THK5117 (10−14 to 10−5 M) and T807 (10−14 to
10−5 M) to determine the off-target binding of the tau
PET tracers. After 2-h incubation at room temperature,
the binding assay was terminated by filtration through
glass fiber filters presoaked for at least 3 h in 0.3%
Table 1 Demographic data
Sex (M/F) Age (years) Braak stage ApoE Postmortem delay (h:minutes)
Regional distribution comparison AD M 78 5 4/4 6:35
F 75 5 4/4 5:50
F 81 5 4/3 6:15
Control F 77 1 3/3 2:55
F 84 1 3/3 6:55
M 81 2 3/3 7:55
3H-THK5351 competition study AD M 77 6 NA 6:35
F 86 6 NA 4:20
F 75 5 4/4 5:50
3H-THK5351 saturation study AD F 75 5 4/4 5:50
Large frozen section autoradiography AD1 N/A 59 N/A 3/3 4:20
AD2 N/A 73 N/A 3/3 1:45
AD3 N/A 59 N/A 3/4 10:45
Abbreviations: AD Alzheimer’s disease, ApoE Apolipoprotein E, N/A Not applicable
Summary of the demographic data for the postmortem brain samples used in the experiments
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polyethylenimine. To do so, the filters were rinsed and fil-
tered three times using cold binding buffer, and then the ra-
diation on the filter was quantified using a Beckman
Coulter scintillation counter. The data from all the binding
studies were analyzed using Prism version 7.0 software.
In vitro autoradiography experiment
Postmortem frozen left brain hemispheres from three pa-
tients with AD were obtained from the Neuropathology of
Dementia Laboratory (Indiana University School of Medi-
cine, Indianapolis, IN, USA) and used for the autoradiog-
raphy experiment. The frozen sections were allowed to
reach room temperature, preincubated for 10 minutes
with PBS + 0.1% BSA (pH 7.4), and then incubated for 1 h
at room temperature with 3H-THK5351 (3 nM) or 3H-
THK5117 (3 nM). The sections were rinsed three times in
cold buffer for 5 minutes, followed by a quick dip in cold
distilled water. Nonspecific binding was determined using
10 μM unlabeled THK5351 or 10 μM unlabeled
THK5117. After waiting 24 h for the sections to dry, the
sections were apposed to a tritium standard on a phos-
phoplate for 3 days and then scanned using a BAS-2500
phosphor imager (Fujifilm, Tokyo, Japan).
Six adjacent sections from AD1 (see Table 1) were
used for competition autoradiography of unlabeled
THK5351, T807, and deprenyl. After reaching room
temperature, the frozen sections were preincubated for
10 minutes with PBS (pH 7.4) and then incubated for
1 h at room temperature with 3H-THK5351 (1.5 nM) in
addition to 10 μM unlabeled THK5351; 10 μM un-
labeled deprenyl; 10 μM unlabeled T807; 10 μM un-
labeled THK5351 and 10 μM unlabeled deprenyl; 10 μM
unlabeled T807 and 10 μM unlabeled deprenyl. The sec-
tions were rinsed three times in cold buffer for 5 mi-
nutes, followed by a quick dip in cold distilled water.
Nonspecific binding was determined using 10 μM un-
labeled THK5351 or 10 μM unlabeled THK5117. After
waiting 24 h for the sections to dry, the sections were
apposed to a tritium standard on a phosphor plate for
3 days and then scanned using the BAS-2500 phosphor
imager.
Adjacent sections were used for autoradiography with
11C-THK5351, 11C-PBB3, and 18F-T807. The frozen sec-
tions were allowed to reach room temperature, incu-
bated for 30 minutes at room temperature with 11C-
THK5351 (0.4–0.56 nM; specific activity 356–532 GBq/
μmol) or 11C-PBB3 (0.25–0.34 nM; specific activity 442–
794 GBq/μmol) or for 55 minutes at room temperature
with 18F-T807 (0.04 nM; specific activity 281 GBq/
μmol). We used 10 μM unlabeled THK5351, 10 μM un-
labeled PBB3, and 10 μM unlabeled T807 to determine
the extent of nonspecific binding for each tracer. The
sections were rinsed three times for 5 minutes each with
cold binding buffer, followed by a quick dip in cold
distilled water. The sections were dried and exposed for
1 h (for 11C-THK5351 and 11C-PBB3) or for 3 h (18 F-
T807) on a phosphor imaging plate and then read using
the BAS-2500 phosphor imager.
For all the autoradiography studies, the regions of
interest were drawn manually on the autoradiogram
using multigauge software and were used for the semi-
quantitative analyses. Photostimulated luminescence per
square millimeter (PSL/mm2) was transformed to pico-
moles per cubic millimeter using a transformation factor
that took into account the resolution of the image, the
pixel value for the concentration of ligand, and the
thickness of the sections: (PSL/mm2 value)/([pixel value
per pmol] × [(resolution/1000)2] × [cryosection thick-
ness]/1000).
Results
Autoradiography studies of 3H-THK5117 and 3H-
THK5351 showed similar regional distribution in both
frontal and temporal cortex areas. An example of the
autoradiography results for AD1 tissue is presented in
Fig. 1.
Regional distribution comparison between THK5351 and
THK5117 using binding assays and autoradiography
The regional binding distributions of 3H-THK5351 and 3H-
THK5117 are shown in Fig. 2 (see Table 1 for demographic
data). The regions studied included the frontal cortex, the
temporal cortex, and the hippocampus. The regional bind-
ing distribution of the two THK compounds was similar in
both AD and control tissue (Fig. 2). The only significant dif-
ference between 3H-THK5351 and 3H-THK5117 binding
was in the temporal cortex, with more extensive binding of
3H-THK5117 than of 3H-THK5351 (p < 0.0001) (Fig. 2).
For all three regions, the extent of binding in control tissue
was significantly lower than in AD tissue.
Saturation curve for 3H-THK5351
The saturation binding assay results from increasing
concentrations of 3H-THK5351 in hippocampus AD
brain homogenate are presented in Fig. 3. Saturation oc-
curred with a Bmax of 76 ± 4.07 pmol/g and a Kd of 5.3 ±
1.16 nM. An additional binding site was observed on the
Scatchard plot. The dotted line in Fig. 3, drawn manu-
ally, shows a Bmax of 40 pmol/mg and a Kd of 1 nM.
Competition binding study comparison between 3H-
THK5351 and unlabeled THK5351, THK5117, and T807
The results of the competition binding study using 3H-
THK5351 and increasing concentrations of unlabeled
THK5351, THK5117, and T807 are presented in Fig. 4.
We observed more than one binding site for the three
unlabeled compounds. THK5117, THK5351, and T807
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Fig. 1 In vitro comparison 3H-THK5351 and 3H-THK5117 binding. Autoradiography comparison of total binding of 3H-THK5117 and 3H-THK5351
on large frozen postmortem brain sections. Red = highest binding; blue = lowest
Fig. 2 Regional binding distribution in brain homogenate. Regional binding distribution of 3H-THK5117 and 3H-THK5351 in postmortem frontal
cortex, temporal cortex, and hippocampus tissue from three patients with Alzheimer’s disease and three control subjects. Error bars represent the
SEM from three experiments in triplicate. Two-way analysis of variance multiple comparisons with Prism software was performed. * p < 0.05, ** p
< 0.005, # p < 0.0001. AD Alzheimer’s disease, FC Frontal cortex, Hip Hippocampus, TC Temporal cortex
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behaved similarly, competing with 3H-THK5351 at low
concentrations. The Ki1 values were 0.1 pM, 0.3 pM, and
0.2 pM for THK5351, THK5117, and T807, respectively
(Fig. 4). The Ki2 values were 16 nM for THK5351 and
20 nM for THK5117. The second competing site for
T807 had a Ki2 value of 78 nM.
Autoradiography comparison and competition between
three tau tracers
Figure 5 shows the regional distribution of three of the
tau PET tracers (T807, THK5351, and PBB3) in adjacent
sections of AD3. 18F-T807 and 11C-THK5351 showed re-
gional binding in both the frontal and temporal cortices.
The regional 11C-PBB3 binding distribution in the cor-
tical area was similar to that for 18F-T807 and 11C-
THK5351, but less intense (Fig. 5). Semiquantitative ana-
lyses indicated that binding was twice as extensive for
11C-THK5351 as for 11C-PBB3. For example, in the
frontal cortex, the binding was 13,500 pmol/mm3 for
11C-THK5351 and 7700 pmol/mm3 for 11C-PBB3 (see
Additional file 1: Tables S1, S2, and S3 for all semiquan-
titative data). The same result was observed in the tem-
poral cortex: 10,500 pmol/mm3 and 6400 pmol/mm3 for
11C-THK5351 and 11C-PBB3, respectively. Binding in
subcortical areas and white matter was observed for
both tracers. The semiquantitative data showed less
binding for 18F-T807 than for 11C-THK5351 or 11C-
PBB3, but the 18F-T807 concentration was ten times
lower, so a direct comparison was not possible.
Figure 6 shows a panel of autoradiography results for
11C-THK5351 and 11C-PBB3, with THK5351, PBB3, and
T807 as unlabeled competitors in AD3 tissue. Visual
assessment indicated that the regional distribution was
similar throughout the whole cortical ribbon for the two
11C tracers (Fig. 6a, d). Qualitatively, 11C-PBB3 seems to be
less extensively bound in white matter. The addition
of unlabeled THK5351 (10 μM) displaced 47% of the
11C-THK5351 binding in the frontal gyrus and 36% in
the temporal region (Fig. 6b). The addition of un-
labeled T807 (10 μM) displaced almost 37% of the
11C-THK5351 binding in the frontal gyrus and 34% in
the temporal region. In the subcortical region, puta-
men, and globus pallidus, T807 blocked 46% of 11C-
THK5351 binding (Fig. 6c).
Similar autoradiography displacement experiments
performed with 11C-PBB3 showed displacement of 56%
with unlabeled PBB3 (10 μM) in the frontal gyrus and
50% in the temporal gyrus (Fig. 6e). The addition of un-
labeled T807 (10 μM) led to 21% blocking in the frontal
gyrus and 11% in the temporal gyrus (Fig. 6f ). Addition
of unlabeled THK5351 to 11C-PBB3 led to 7% inhibition
of binding in the frontal cortex and 18% in the temporal
cortex (Fig. 6g). The semiquantitative analyses are pre-
sented in Table 2, which shows the mean percentage in-
hibition of binding for 11C-PBB3 and 11C-THK5351 on
addition of the unlabeled competitor in three AD tissue
samples (see Additional file 1: Tables S1, S2, and S3 for
the total binding, nonspecific binding, and specific bind-
ing values for each brain sample, respectively).
Competition binding study between 3H-deprenyl and
unlabeled THK5117 or T807
The results of competition binding studies between 3H-
deprenyl and unlabeled THK5117 or T807 in the
Fig. 3 Saturation binding assay. Saturation binding curve in hippocampus brain homogenate using increasing concentrations of 3H-THK5351
(0.1–150 nM) and the corresponding Scatchard plot. Kd Dissociation constant
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hippocampus and putamen brain homogenates are pre-
sented in Fig. 7. Competition with 3H-deprenyl was ob-
served in the hippocampus, with Ki values of 286 nM for
THK5117 and 227 nM for T807. Similar results were
obtained in the putamen, with Ki values of 148 nM for
THK5117 and 135 nM for T807.
Competition autoradiography binding study comparison
between 3H-THK5351 and unlabeled THK5351, deprenyl,
and T807
Figure 8 shows the competition autoradiography results
from large frozen brain sections, with 3H-THK5351 in
competition with unlabeled THK5351, deprenyl, or
T807, as well as combinations of the unlabeled com-
pounds. In this set of experiments, unlabeled THK5351
displaced about 70% of the 3H-THK5351 binding in the
frontal and temporal cortical areas and 61% in the basal
ganglia (Fig. 8b). Unlabeled T807 displaced about 70–
74% of 3H-THK5351 binding in the frontal and temporal
cortices and up to 77% in the basal ganglia (Fig. 8c).
Unlabeled deprenyl displaced more than 40% in both
frontal and temporal cortices but more than 50% in the
basal ganglia (Fig. 8d).
Discussion
The aim of this study was to compare, using in vitro
binding assays and in vitro autoradiography, the avail-
able tau PET tracers in the same postmortem tissue
from patients with AD. The comparison of the two THK
compounds, THK5117 and THK5351, is discussed first.
THK5117 was developed as a tau PET ligand and was
found to bind to white matter in the brain. THK5351,
the latest THK compound, was developed as a pure S-
form enantiomer to lower white matter binding [24].
The saturation binding curve of 3H-THK5351 showed
two binding sites and good binding properties, with a Kd
of 5 nM in the range of the optimum Kd for a PET
tracer. These results are similar to those obtained with
THK5117, which also had two binding sites in the satur-
ation experiments [10]. The head-to-head direct com-
parison between the two THK compounds using single
concentration binding assays in several brain regions
showed similar distribution patterns in all the regions
studied. These results confirm that the S-form is the
only active form because we used half the concentration
for 3H-THK5351 as we did for 3H-THK5117. Autoradi-
ography with frozen hemispheric coronal sections
showed similar distribution patterns throughout the cor-
tical ribbon as well as a similar lamination binding pat-
tern, indicating that the tracers target the same tau
deposits. We observed more nonspecific binding with
THK5117 than with THK5351.
In this study, the binding assay competition between
3H-THK5351 and unlabeled THK5117, unlabeled
THK5351, and unlabeled T807 showed that the three
unlabeled tracers compete with 3H-THK5351 for at least
two binding sites. The THK compounds bind to two
similar binding sites: one with a high affinity (Ki1 0.2
pM) and the other with a much lower affinity (Ki2 ap-
proximately 20 nM). T807 seems to behave differently
from 3H-THK5351. Indeed, it was clear that even though
it competed for the same high-affinity binding site, T807
competed with fourfold less affinity than THK5351, in
the nanomolar range (Ki2 76 nM). This suggests that tar-
geting of the binding sites in the nanomolar range visible
in PET studies will probably differentiate between T807
and the THK compounds. To our knowledge, this is the
first study comparing the three families of tau PET
tracers in the same brain tissue. The slightly different re-
sults observed between 3H and 11C autoradiography
studies were most probably due to the emission type as
well as to the special protocols needed for the different
isotopes. All the autoradiography protocols have been
optimized in-house in order to use the optimal binding
Fig. 4 Competition binding assay with 3H-THK5351 and unlabeled
THK5351, THK5117, and T807. Competition binding studies using 3H-
THK5351 (1.5 nM) binding in postmortem hippocampus brain
homogenates from three patients with Alzheimer’s disease using
increasing concentrations of unlabeled THK5351, unlabeled THK5117, or
unlabeled T807 (1.10−14 to 1.10−5 M). Error bars represent the SEM from
three experiments in triplicates using two tissue samples for unlabeled
THK5351 and THK5117 and three tissue samples for unlabeled T807. Ki
Inhibition constant
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Fig. 6 11C-THK5351 and 11C-PBB3 autoradiography competition with unlabeled THK5351, PBB3, and T807. The percentage inhibition of binding
by the unlabeled compound in AD3 tissue for 11C-THK5351 and 11C-PBB3 autoradiography. a–c 11C-THK5351 autoradiography. a Total binding. b
Competition with 10 μM unlabeled THK5351. c Competition with 10 μM unlabeled T807. d–g 11C-PBB3 autoradiography. d Total binding. e
Competition with 10 μM unlabeled PBB3. f Competition with 10 μM unlabeled T807. g Competition with 10 μM unlabeled THK5351
Fig. 5 18F-T807, 11C-THK5351, and 11C-PBB3 autoradiography comparison of large frozen postmortem brain sections from AD3. The figure shows
the total binding of 18F-T807, 11C-THK5351, and 11C-PBB3
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condition. No ethanol was used in either the binding or
rinsing buffer. Three previous studies have compared
the different tau PET tracer families in two-by-two
batches. The first compared 11C-PBB3 and 18F-AV1451
[25]; the second compared 3H-AV1451 and 3H-THK523
(one of the first-generation THK compounds) [26]; and
the third compared 18F-T808 (in the same family as
T807) and THK5105 (THK family compound) [27].
Autoradiography studies on frozen hemispheric brain
sections using 11C-THK5351 are reported for the first
time in this study, to our knowledge. Visual assessment
showed similar regional binding distributions for 18F-
T807, 11C-THK5351, and 11C-PBB3 in all the analyzed
regions. However, using semiquantitative analyses, the
specific binding values for 11C-PBB3 were lower than
those for 11C-THK5351. This difference in binding
Fig. 7 3H-Deprenyl (3H-DED) competition with unlabeled THK5351 and T807. Competition binding studies using increasing concentrations of
unlabeled THK5117 or unlabeled T807 (1.10−14 to 1.10−5 M) with 3H-DED in hippocampus (a) and putamen (b) brain homogenates of two
Alzheimer’s disease (AD) cases. Error bars represent the SEM of two experiments in triplicate for two AD cases. Ki Inhibition constant
Table 2 Semiquantitative analysis of competition autoradiography using 11C-THK5351, 11C-PBB3, 18F-T807, and unlabeled THK5351,
PBB3, and T807
+ Unlabeled THK5351 (% inhibition) + Unlabeled PBB3 (% inhibition) + Unlabeled T807 (% inhibition)
11C-THK5351
Frontal cortex −52 ± 15 Experiment not performed −27 ± 10
Insula −43 ± 14 −27 ± 2
Temporal cortex −41 ± 15 −29 ± 13
Basal ganglia −49 ± 17 −42 ± 5
11C-PBB3
Frontal cortex −22 ± 5 −53 ± 3 −18 ± 3
Insula −19 ± 1 −46 ± 2 −14 ± 6
Temporal cortex −27 ± 9 −50 ± 9 −9 ± 4
Basal ganglia −21 ± 3 −48 ± 1 −18 ± 4
18F-T807
Frontal cortex Experiment not performed Experiment not performed −35 ± 10
Insula −27 ± 8
Temporal cortex −30 ± 15
Basal ganglia −26 ± 4
This table shows the extent of inhibition of binding (as a percentage) by unlabeled T807 of 11C-THK5351 by unlabeled THK5351 and T807; of 11C-PBB3 by
unlabeled THK5351, PBB3, and T807; and of 11C-T807. The values presented are mean ± SD of values from three Alzheimer’s disease brain samples
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intensity may be the result of the molecules targeting
different subtypes of tau deposit, which express binding
sites with different binding affinities. The semiquantita-
tive data for 18F-T807 were also lower than for either
11C-THK5351 or 11C-PBB3, but the concentrations used
for the autoradiography were ten times lower because of
the high radioactivity of 18F.
The addition of unlabeled T807 decreased the ability
to block 11C-PBB3 binding compared with 11C-
THK5351 binding. Those results support the binding
assay data. Indeed, the THK compound and T807 seem
to share similar binding sites, although they do not have
the same affinity for them. In the autoradiography stud-
ies, we also observed that unlabeled T807 displaced the
binding of 11C-THK5351 in the subcortical regions
slightly more than in the cortical region, confirming the
off-target binding of T807 in the subcortical region.
Only a few studies are available to compare different
tau tracer binding sites in the same populations.
Declercq et al. recently compared THK5105 and T807 and
suggested a possible similar binding site for the two tracers
[27]. Cai et al. designed a study to develop a new tau de-
posit tracer with high affinity compared THK523 and T807
with PIB. Their study suggested that THK523 and T807
have two separate binding sites on the NFTs and that those
binding sites differ from the thioflavin-T binding site tar-
geted by amyloid PET tracers [26]. In our study, both 11C-
THK5351 and 18F-T807 showed binding in the basal gan-
glia region. Both THK5351 and AV1451 in vivo PET have
shown high binding in the basal ganglia, probably at least
partly reflecting off-target binding to MAO-A and MAO-B
[15]. Recently, Ng et al. [20] demonstrated a diminution of
18F-THK5351 binding in patients after treatment with sele-
giline (deprenyl) (protocol consisting of one baseline 18F-
THK5351 scan, then 1 week later, a second 18F-THK5351
scan 1 h after 10-mg oral dose of selegiline). Owing to our
observation of similar MAO-B components for both
THK5351 and T807, it would be important to perform
Fig. 8 3H-THK5351 autoradiography competition with unlabeled THK5351, T807, and deprenyl. 3H-THK5351 comparisons in large frozen
postmortem brain sections from a patient with Alzheimer’s disease (AD1). a Total binding (1.5 nM of 3H-THK5351). b Competition with 10 μM
unlabeled THK5351. c Competition with 10 μM unlabeled T807. d Competition with 10 μM unlabeled deprenyl. e Competition with 10 μM
unlabeled THK5351 + 10 μM unlabeled deprenyl. f Competition with 10 μM unlabeled T807 + 10 μM unlabeled deprenyl. The percentage
inhibition of binding by the unlabeled compounds in AD1 tissue for the various regions is marked
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similar experiments with in vivo 18F-T807 PET scans fol-
lowing the pretreatment with selegiline. The in vitro 3H-
deprenyl binding competition assay with unlabeled
THK5117 and unlabeled T807 showed an affinity of ap-
proximately 150 nM for both in the putamen and greater
than 200 nM in the hippocampus. For tau binding, the Ki
values of THK5117 and T807 are, respectively, 20 nM and
78 nM toward 3H-THK5351. The results of the autoradiog-
raphy competition studies with unlabeled T807, THK5351,
and deprenyl (selegiline) showed that unlabeled T807 dis-
placed 3H-THK5351 binding as much as unlabeled
THK5351 in the frontal and temporal cortices, but more in
the basal ganglia. These results confirm our hypothesis that
THK5351 and T807 behave similarly in AD brain tissue.
Unlabeled deprenyl alone displaced more binding in the
basal ganglia, a region richer in MAO-B. PBB3 seems to
bind differently and to have a unique regional distribution.
Moreover, a recent study by Ono et al. [25], who compared
T807 and PBB3 head to head, showed that the two com-
pounds bound to different sites. Regarding the MAO-A, a
previous study has shown interaction with MAO-A for
T807 [22, 23]. Note that in the present study we assessed
the MAO-A component only for 3H-THK5117 using clor-
gyline (MAO-A inhibitor) and found a Ki value of 273 nM
for clorgyline toward 3H-THK5117 (see Additional file 2:
Figure S2).
This study has several limitations. It is important to note
the differences in techniques between in vitro autoradiog-
raphy on large frozen tissue sections (80 μm thick) and
binding assays in brain homogenates. Indeed, the binding
assay in brain homogenates might make more binding
sites accessible for binding in comparison to in vitro auto-
radiography. Moreover, we used different isotopes—3H,
11C, and 18F—with different energy and emission, which
could also be a limitation of the study. However, we con-
sider that those different techniques provide valuable
complementary information for the characterization of
the different tracers. This is important to understanding
the different binding sites of the tau PET tracers.
In this study, we focused on the THK compounds as
well as PBB3 and T807. Recently, some new tau PET
tracer candidates have been reported both at inter-
national congresses and in the literature: 18F-MK6240;
18F-RO6958948; 18F-GTP1 (Genentech Tau Probe 1);
18F-PI2620; 18F-JNJ64349311; and new analogues of
PBB3, 18F-AM-PBB3 and 18F-PM-PBB3 [22, 28–31]. It
will be interesting in the future to perform head-to-head
comparisons including these new tau PET tracers.
Interestingly, the cryo-electron microscopic structure
of tau fibrils was recently reported by Fitzpatrick et al.
[32]. This new knowledge will allow in silico computer
modeling and determination of different binding sites on
the tau fibrils, similar to what has already been done for
the amyloid fibrils [33]. This will also help in the
characterization and optimization of tau PET tracers
using in silico modeling and radiochemistry. Even
though we still have to keep in mind that in silico and in
vitro behavior is not the same as in vivo, the comple-
mentarity of all the different techniques is important for
the characterization of PET tracers.
Conclusions
To our knowledge, this is the first study to compare PBB3,
T807, and THK5351 in the same AD brain tissue samples
using both brain homogenate and autoradiography studies.
The head-to-head comparison suggests that the THK com-
pound and T807 target similar binding sites with different
affinities but that PBB3 seems to target its own site. Both
THK5351 and T807 show off-target binding to MAO-B
with affinity similar to that of deprenyl. It is important to
carry out more in vitro characterization of these com-
pounds before proceeding to clinical studies. Indeed, the
different PET tracers seem to bind to different subtypes of
tau deposit; thus, knowing exactly what kind of tau deposit
is being targeted could help with the diagnosis and add in-
formation about the neuropathological sequence.
Additional files
Additional file 1: Table S1. Semi-quantitative analysis of 11C-THK5351
autoradiography in competition with unlabelled THK5351 and unlabelled
T807. Unlabelled PBB3 was not studied. Specific binding was calculated
as total binding minus non-specific (NSP) binding. Table S2. Semi-
quantitative analysis of 11C-PBB3 autoradiography in competition with un-
labelled THK5351, unlabelled T807 and unlabelled PBB3. Specific binding
was calculated as total binding minus non-specific (NSP) binding. Table
S3. Semi-quantitative analysis of 18F-T807 autoradiography in competition
with unlabelled T807. Neither unlabelled THK5351 nor unlabelled PBB3
were studied. Specific binding was calculated as total binding minus
non-specific (NSP) binding. (DOCX 109 kb)
Additional file 2: Figure S1. Competition binding assay with H-
THK5117 and unlabelled clorgyline. Competition binding studies using
3H-THK5117 (3nM) binding in hippocampus brain homogenate from one
AD cases using increasing concentration of clorgyline (10-14 -10-5). Errors
bars represent the standard errors of the mean from three experiments in
triplicate. (DOCX 229 kb)
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